We are live on
!
Find out more
WIM
Woodford Investment Management Portfolio holdings
AUM
$310M
1-Year Est. Return
17.41%
This Fund
S&P 500
This Quarter
Est. Return
+7.16%
1 Year Est. Return
-17.41%
3 Year Est. Return
-27.14%
5 Year Est. Return
+68.29%
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
-$544M
(-20%)
Cap. Flow
-$673M
Cap. Flow
% of AUM
-30.9%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
7
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$607M |
| 2 |
Gilead Sciences
GILD
|
+$42.4M |
| 3 |
Alkermes
ALKS
|
+$16.7M |
| 4 |
Prothena Corp
PRTA
|
+$3.11M |
| 5 |
Biogen
BIIB
|
+$2.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
LCM
GWA
NC
IPC
AEPG
AR
KCM
COI
Woodford Investment Management's Q3 2017 Portfolio in Review
As of Q3 2017, Woodford Investment Management held 7 positions worth $2.18B, down 20% from $2.72B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Woodford Investment Management withdrew a net $673M in Q3 2017, reducing 7 holdings. Its largest reduction was AbbVie, cutting an estimated $607M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Woodford Investment Management's biggest Q3 2017 reduction was AbbVie, cutting an estimated $607M.
- Woodford Investment Management's ten largest holdings make up 100% of its $2.18B portfolio in Q3 2017.
- Woodford Investment Management opened 0 new positions and closed 0 in Q3 2017.
- Woodford Investment Management's portfolio value fell 20% quarter-over-quarter to $2.18B.
Based on Woodford Investment Management's 13F filing for Q3 2017, filed 1 Nov 2017.